Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment
NEW ORLEANS and LONDON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment taking place in Basel, Switzerland from September 21-22.
Revolo’s Group Chief Executive Officer, Jonathan Rigby, and Chief Scientific Officer, Dr. Rely Foulkes, will present a corporate overview on Wednesday, September 21 at 12:00 p.m. CEST (6:00 a.m. EDT). In addition, Dr. Foulkes will join an expert panel discussion on autoimmune and inflammatory diseases on Thursday, September 22 at 11:10 a.m. CEST (5:10 a.m. EDT).
The Sachs Associates Biotech in Europe Forum is highly transactional and is comprised of a series of panels and presentations from leading investment, pharmaceutical and biotech companies. The full agenda for the forum can be accessed here.
About Revolo Biotherapeutics
For further information, please visit www.revolobio.com.